Guselkumab Shows Durable Joint and Skin Response Through Week 48

The phase 3b APEX trial reported 48-week outcomes in 1020 biologic-naive adults with active, erosive psoriatic arthritis treated with guselkumab Q4W, guselkumab Q8W, or placebo-to-guselkumab crossover at week 24. Both guselkumab regimens maintained ACR20/50/70 response rates (71-74%/51-56%/31-35%), low structural damage progression, and high rates of PASI90 and MDA; participants who switched from placebo to guselkumab showed reduced structural progression and increasing clinical response rates after the switch. Adverse event rates remained stable from week 24 through week 48.

Most relevant for: Biologic-naive adults with active and erosive psoriatic arthritis being considered for IL-23 inhibitor therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.